Original Sky Meter Intranet
Highlights
Recently, the official website of the State Food and Drug Administration announced that the application for the protection of traditional Chinese medicine was accepted. This product is Kangyuan Pharmaceutical's exclusive chronic renal failure treatment drug (including exclusive dosage form, the same below), and the terminal sales growth rate of physical pharmacies in Chinese cities in 2022 and the first half of 2023 will exceed 469% and 232%, respectively.
Source: official website of the State Food and Drug Administration
According to the data, Shenwu Yi Kidney Tablets are mainly composed of Polygonum multiflori, Cuscuta seed, Prince's ginseng, fried atractylodes with bran, wolfberry, etc., which have the effects of tonifying the kidney and strengthening the spleen, invigorating blood and relieving dampness, and are often used to improve chronic renal failure caused by chronic glomerulonephritis (compensated, decompensated and exhausted) in non-dialysis patients with qi and yin deficiency and dampness and turbidity syndrome, such as nausea, vomiting, lack of appetite, dry mouth and throat, dry stool, etc.
In recent years, the sales trend of ginseng Wuyi kidney tablets in China's three major terminals and six major markets (unit: 10,000 yuan)
Source: Minenet Grid Bureau Database
In recent years, the total sales scale of Shenwuyi Kidney Tablets in China's three major terminals and six major markets (see the end of this article for details) has expanded year by year, of which the terminals of public medical institutions are the main battlefield, accounting for more than 86% of the market in 2022, while the sales growth rate of the drug in urban physical pharmacies in 2022 and the first half of 2023 will exceed three digits, with 469.23% and 232.56% respectively.
Kangyuan Pharmaceutical Co., Ltd. was previously in the protection period of the second-class protected varieties of traditional Chinese medicine
Source: Minenet Catalogue Database of Protected Varieties of Traditional Chinese Medicine
In the past 2023, Kangyuan Pharmaceutical has 2 exclusive proprietary Chinese medicines protected, including Qiwei Tongbi Oral Liquid for rheumatoid arthritis and Ginkgo Diterpene Lactone Meglumine Injection for ischemic stroke. According to data from Minenet, prior to this, the company has 2 second-level protected varieties of traditional Chinese medicine in the protection period, namely Jiuwei Qufeng Granules for the treatment of pediatric multiple tics (protection termination date: October 29, 2025), and Epimedium total flavonoid capsules for the treatment of osteoporosis (protection termination date: September 5, 2029), covering pediatric convulsion drugs, osteoporosis drugs and other treatment subclasses.
Source: Minenet database, official website of the State Food and Drug Administration
Note: The statistical scope of "China's Three Terminals and Six Major Markets" is as follows: urban public hospitals and county-level public hospitals, urban community centers and township health centers, urban physical pharmacies and online pharmacies, excluding private hospitals, private clinics, village clinics, and county and rural pharmacies; Statistics as of January 8, if there is any omission, please correct!